4.6 Article

Lung function decline in relation to mould and dampness in the home: the longitudinal European Community Respiratory Health Survey ECRHS II

期刊

THORAX
卷 66, 期 5, 页码 396-401

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/thx.2010.146613

关键词

-

资金

  1. European Commission
  2. Fondo de Investigaciones Santarias (FIS), Albacete [97/0035-01, 99/0034-01, 99/0034-02]
  3. Hospital Universitario de Albacete, Albacete
  4. Consejeria de Sanidad, Albacete
  5. FWO (Fund for Scientific Research)-Flanders Belgium, Antwerp [G.0402.00]
  6. University of Antwerp, Antwerp
  7. Flemish Health Ministry, Antwerp
  8. SEPAR, Public Health Service, Barcelona [R01 HL62633-01]
  9. Fondo de Investigaciones Santarias (FIS), Barcelona [97/0035-01, 99/0034-01, 99/0034-02]
  10. CIRIT, Barcelona [1999SGR 00241]
  11. 'Instituto de Salud Carlos III' Red de Centros RCESP, Barcelona [C03/09, C03/011]
  12. Swiss National Science Foundation, Basel
  13. Swiss Federal Office for Education Science, Basel
  14. Swiss National Accident Insurance Fund (SUVA), Basel
  15. Norwegian Research Council, Norwegian Asthma & Allergy Association (NAAF), Bergen
  16. Glaxo Wellcome AS, Bergen
  17. Norway Research Fund, Bergen
  18. Institut Pneumologique d'Aquitaine, Bordeaux
  19. GSF-National Research Centre for Environment Health, Erfurt
  20. Deutsche Forschungsgemeinschaft (DFG), Erfurt [FR 1526/1-1]
  21. Basque Health Department, Galdakao
  22. Swedish Heart Lung Foundation, Goteborg
  23. Swedish Foundation for Health Care Sciences & Allergy Research, Goteborg
  24. Swedish Asthma & Allergy Foundation, Goteborg
  25. Swedish Cancer & Allergy Foundation, Goteborg
  26. Programme Hospitalier de Recherche Clinique-DRC de Grenoble, Grenoble [2610]
  27. Ministry of Health, Direction de la Recherche Clinique, Grenoble
  28. Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, Grenoble
  29. CHU de Grenoble, Grenoble
  30. Comite des Maladies Respiratoires de l'Isere, Grenoble
  31. GSF-National Reasearch Centre for Environment & Health, Hamburg
  32. Deutsche Forschungsgemeinschaft (DFG), Hamburg [MA 711/4-1]
  33. Asthma UK (formerly known as National Asthma Campaign) (UK), Ipswich and Norwich
  34. Fondo de Investigaciones Santarias (FIS), Huelva [97/0035-01, 99/0034-01, 99/0034-02]
  35. Programme Hospitalier de Recherche Clinique-DRC de Grenoble, Montpellier [2610]
  36. Ministry of Health, Direction de la Recherche Clinique, Montpellier
  37. CHU de Grenoble, Montpellier
  38. Ministere de l'Emploi et de la Solidarite, Montpellier
  39. Direction Generale de la Sante, Montpellier
  40. Aventis (France), Montpellier
  41. Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon, Montpellier
  42. Fondo de Investigaciones Santarias (FIS), Oviedo [97/0035-01, 99/0034-01, 99/0034-02]
  43. Ministere de l'Emploi et de la Solidarite, Paris
  44. Direction Generale de la Sante, Paris
  45. UCB-Pharma (France), Paris
  46. Aventis (France), Paris
  47. Glaxo France, Paris
  48. Programme Hospitalier de Recherche Clinique-DRC de Grenoble, Paris [2610]
  49. Ministry of Health, Paris
  50. Direction de la Recherche Clinique, Paris
  51. CHU de Grenoble, Paris
  52. Glaxo-SmithKline Italy, Pavia
  53. Italian Ministry of University and Scientific and Technological Research (MURST), Paris
  54. Local University (Pavia, Italy)
  55. American Lung Association of Oregon, Portland
  56. Northwest Health Foundation, Portland
  57. Collins Foundation, Portland
  58. Merck Pharmaceutical, Portland
  59. Icelandic Research Council, Reykjavik
  60. Icelandic University, Reykjavik
  61. Estonian Science Foundation, Tartu
  62. ASL 4 Regione Piemonte (Italy), Turin
  63. AO CTO/ICORMA Regione Piemonte (Italy), Turin
  64. Ministero dell'Universita e della Ricerca Scientifica (Italy), Turin
  65. Glaxo Wellcome spa (Verona, Italy), Turin
  66. Swedish Heart Lung Foundation, Umea
  67. Swedish Foundation for Health Care Sciences & Allergy Research, Umea
  68. Swedish Asthma & Allergy Foundation, Umea
  69. Swedish Cancer & Allergy Foundation, Umea
  70. Swedish Heart Lung Foundation, Uppsala
  71. Swedish Foundation for Health Care Sciences & Allergy Research, Uppsala
  72. Swedish Asthma & Allergy Foundation, Uppsala
  73. Swedish Cancer & Allergy Foundation, Uppsala
  74. Medical Research Council [G0801056B] Funding Source: researchfish

向作者/读者索取更多资源

Background There are few longitudinal studies that have examined the association of lung function decline with indoor mould and dampness. Lung function decline in relation to dampness and mould in the home has studied in adults over a 9 year period. Methods Spirometry was performed twice in participants in the European Respiratory Health Survey (ECRHS I and II) who were initially examined aged 20-45 years, in 1990-1995 and 9 years later (n=6443). Information on their current home was collected twice by interview. Dampness (water damage or damp spots) and indoor mould, ever and in the last 12 months, were assessed. A dampness score and a mould score were calculated. In addition, 3118 homes at 22 centres were inspected directly at follow-up for the presence of dampness and mould. Results Dampness and mould were common. Overall, 50.1% reported any dampness and 41.3% any indoor mould in either ECRHS I or ECRHS II. Women with dampness at home had an additional decline in forced expiratory volume in 1 s (FEV1) of -2.25 ml/year (95% CI -4.25 to -0.25), with a significant trend in increased lung function decline in relation to the dampness score (p=0.03). The association in women was significant when excluding those with asthma at baseline. Observed damp spots in the bedroom was associated with a significant additional decline in FEV1 of -7.43 ml/year (95% CI -13.11 to 1.74) in women. Conclusion Dampness and indoor mould growth is common in dwellings, and the presence of damp is a risk factor for lung function decline, especially in women.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据